Hymenoptera Venom Immunotherapy: Immune Mechanisms of Induced Protection and Tolerance.
Ajda Demšar Luzar, Peter Korošec, Mitja Košnik...
https://pubmed.ncbi.nlm.nih.gov/34206562/Actively Recruiting
Led by Inmunotek S.L. · Updated on 2025-05-04
120
Participants Needed
9
Research Sites
13 weeks
Total Duration
Researchers are conducting an observational study to assess the safety of immunotherapy for treating Hymenoptera venom allergy, which is an allergic reaction to stings from insects like bees Apis mellifera or wasps Vespula spp.. The study also aims to evaluate how patients quality of life changes before and after receiving immunotherapy. This research will take place across multiple centers in Spain and gather data prospectively. Participants in this study are people aged 14 years and older who are allergic to Hymenoptera venom and have been recommended to receive immunotherapy with VENOX, an allergy vaccine targeting the venom of wasps or bees. The study involves monitoring patients receiving this immunotherapy as part of their clinical care, without any placebo or control group, focusing on real-world treatment safety and patient experience. During the study, participants will be followed for up to 12 months to track any adverse reactions to the immunotherapy and allergic reactions to natural insect stings. Quality of life will be assessed using questionnaires before and after treatment. Researchers will also evaluate immune response at 6 and 12 months and monitor treatment effectiveness once maintenance dosing is reached. Data collection will include safety, tolerability, and patient-reported outcomes to understand the impact of immunotherapy in real clinical settings.
CONDITIONS
Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy
M
Miguel Casanovas, MD
R
Raquel Caballero, BSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Inmunotek S.L.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 months
Participants receive immunotherapy with VENOX allergy vaccine against Hymenoptera venom as per clinical recommendation.
Regular visits as per clinical practice during immunotherapy
Duration - 12 months
Participants are observed for adverse reactions, immunogenicity, quality of life, and effectiveness of immunotherapy during and after treatment.
Assessments at 6 and 12 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Ajda Demšar Luzar, Peter Korošec, Mitja Košnik...
https://pubmed.ncbi.nlm.nih.gov/34206562/J Bousquet, U R Müller, S Dreborg...
https://pubmed.ncbi.nlm.nih.gov/3310714/Joanne N G Oude Elberink, Jan G R De Monchy, Sicco Van Der Heide...
https://pubmed.ncbi.nlm.nih.gov/12110838/David B K Golden
https://pubmed.ncbi.nlm.nih.gov/15753884/Inmunotek S.L.
Lead Sponsor